Guided Therapeutics, Inc. GTHP
Set alert
0.13 USD -0.02 -13.33%
As of Nov 2, 12:20 PM ET
0.13 Day range 0.1301
0.13 52-week range 0.54
- YTD
- -75.93%
- 1 year
- -51.85%
- Open
- 0.1301
- Prev close
- 0.15
- Mkt cap
- 12.55M
- Vol
- 211.00K
- Avg vol
- 26.92K
- EPS
- -0.04
- P/E
- 0.00
More statistics
- Low
- 0.13
- High
- 0.1301
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -0.01 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.01 | — | — |
| May 13, 2024 | Mar 1, 2024 | 0.00 | -0.01 | — | — |
| Mar 28, 2024 | Dec 1, 2023 | 0.00 | 0.00 | — | — |
| Aug 18, 2021 | Jun 1, 2021 | 0.00 | -0.09 | — | — |
| Jul 7, 2020 | Mar 1, 2020 | 0.00 | 0.04 | — | — |
News
- Guided Therapeutics Inc. (OTCMKTS:GTHP) Shares Shorted: Short Interest Up 55.0% in September
- Guided Therapeutics Reaches Collaborative Agreement with Türkiye's Ministry of Health to Become Primary Screening Test for Cervical Cancer
- Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor
- Guided Therapeutics Receives $80,000 Payment as Fourth Installment of $700,000 Purchase Order with Chinese Distributor
- Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA
- Guided Therapeutics Files Premarket Approval Application Clinical Report with FDA
- Haemonetics (NYSE:HAE) vs. Guided Therapeutics (OTCMKTS:GTHP) Head to Head Review
- Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
- Guided Therapeutics (OTCMKTS:GTHP) Shares Down 12.7% – Time to Sell?
- Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
Your note
Sign in to keep a note on GTHP — it syncs with the Stock Master app.